Enormous progress has been made in the understanding of the hepatitis C virus and the development of novel therapeutic agents since the identification of the virus 25 years ago. From initial interferon monotherapy providing only 6% viral clearance rate in the 1980s, pharmacotherapeutics has now entered an exciting new era with direct-acting antiviral agents demonstrating viral clearance rates of more than 70%. We are now at the beginning of an era where combinations of direct-acting antiviral agents may pave the way for interferon-free regimens, even improving the viral clearance rate to near 100%.
Keywords: boceprevir; daclatasvir; danoprevir; deleobuvir; direct-acting antiviral therapy; faldaprevir; hepatitis C; protease inhibitors; simeprevir; sofosbuvir; telaprevir.